Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q1 2023 Earnings Presentation

32 slides from Walgreens Boots Alliance's earnings presentation, Jan 5, 2023

  1. Slide 1: Reimagining Local Healthcare and Wellbeing for All

    Reimagining Local Healthcare and Wellbeing for All First Quarter Fiscal 2023 Results January 5, 2023 © 2023 Walgreens Boots Alliance, Inc. All rights reserved.

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Solid start to fiscal 2023 with accelerated transformation to healthcare

    Solid start to fiscal 2023 with accelerated transformation to healthcare • Solid first quarter performance, broadly in line with expectations • Resilient core business with U.S. retail and Boots UK retail growth on top of strong prior year performances; U.S. script volume growth on track • VillageMD

  4. Slide 4: Continued rapid progress across our four strategic priorities

    Continued rapid progress across our four strategic priorities • U.S. retail comp sales ex. tobacco +2.1% on top of +11.7% last year; continued margin expansion • U.S. pharmacy comp scripts +2.1% ex. immunizations Transform and align the core • Walgreens administered 8.4 million COVID-19 vaccinations

  5. Slide 5: Leading healthcare assets delivering value across the care continuum

    Leading healthcare assets delivering value across the care continuum Primary & Wellness & prevention Pre-acute multi-specialty care Specialty care Post-acute Retail Pharmacy Health Corners Retail pharmacy services, Pharmacist-led chronic Value-based primary care Specialty care and Post-acute care se

  6. Slide 6: 1Q 2023 financial highlights

    1Q 2023 financial highlights • 1Q 2023 adj. EPS of $1.16 vs. prior year adj. EPS of $1.68, down 29.9% on a constant currency basis − Lapping strong growth of 53.1% in the year-ago quarter which was boosted by higher COVID-19 vaccines (U.S., UK) − 5% headwind from U.S. Healthcare; 1Q results reflect

  7. Slide 7: WBA 1Q23 Financial Highlights

    Reported Fx Constant Fx 1Q23 $ in millions (except EPS) B/(W) vs. 1Q22 B/(W) vs. 1Q22 Sales 33,382 (1.5)% + 1.1% Operating Income GAAP ($6,151) ($7,434) WBA 1Q23 Adjusted $1,014 (42.9)% (42.2)% Financial Net Earnings GAAP ($3,721) ($7,301) Highlights Adjusted $1,004 (31.0)% (30.2)% EPS GAAP ($4.31)

  8. Slide 8: U.S. Retail Pharmacy Financials

    1Q23 B/(W) vs. 1Q22 $ in millions Sales $27,204 (3.0)% Adj. gross profit $5,910 (7.2)% Adj. SG&A % of sales 18.2% (1.0)%p U.S. Retail Adj. operating income $1,105 (34.6)% Pharmacy Adj. operating margin1 3.6% (2.0)%p Financials • AllianceRx sales decline was a (590) bps headwind with minimal impact o

  9. Slide 9: U.S. Pharmacy

    1Q23 Total 1Q23 Comparable 1Q23 vs. 1Q22 Pharmacy sales (4.2)% + 4.8% Prescriptions (0.7)% 0.0% Prescriptions ex. Immunizations + 1.4% + 2.1% • Comp sales +4.8% primarily due to brand inflation U.S. Pharmacy • Comp scripts flat; excluding immunizations, comp scripts +2.1% − 8.4 million COVID-19 vacc

  10. Slide 10: U.S. Retail

    1Q23 1Q23 vs. 1Q22 Total retail sales + 0.8% Comparable retail sales + 1.4% • Comp retail sales +1.4%, lapping a strong quarter with comp sales of +10.6% U.S. Retail − Comp excluding tobacco +2.1%, aided by strong cough, cold, flu sales +220 bps partially offset by 170 bps headwind from lower sales

  11. Slide 11: International Financials

    Constant Fx 1Q23 $ in millions B/(W) vs. 1Q22 Sales $5,189 + 4.6% Adj. gross profit $1,050 + 2.1% Adj. SG&A % of sales 18.0% (0.2)%p International Adj. operating income $116 (20.3)% Financials Adj. operating margin 2.2% (0.7)%p • Sales increase reflects Boots UK +4.3% and Germany wholesale +4.2% • A

  12. Slide 12: Boots UK Financials

    1Q23 1Q23 vs. 1Q22 Pharmacy comp. sales (0.9)% Retail comp. sales + 8.7% Boots UK • Pharmacy comp sales lapping strong demand for COVID-19 services in the prior year period • Retail market share growing, notably in health and wellness, and personal care Financials • Strong 1Q retail comp sales, now

  13. Slide 13: U.S. Healthcare Financials

    1Q23 B/(W) vs. 1Q22 $ in millions Sales $989 + $938 Adj. gross profit $43 + $23 Adj. SG&A $(195) $(162) Adj. operating loss $(152) $(139) U.S. Healthcare Adj. EBITDA $(124) $(113) Financials • U.S. Healthcare pro forma sales growth +38% − VillageMD +49%: existing clinic growth, footprint expansion −

  14. Slide 14: U.S. Healthcare Key Metrics

    Current Status1 Contracted Lives >26M Organic Contracted Lives2 2.9M Organic Partners (Payor/Provider)2 3 VillageMD Value-Based Lives3 441K Sites of Care: Health Corners 112 U.S. Healthcare VillageMD Co-Located Clinics 200 Key Metrics Total VillageMD Clinics 393 Pro Forma YOY $ millions 1Q23 Growth

  15. Slide 15: Cash Flow

    B/(W) 1Q23 $ in millions vs. 1Q22 Operating cash flow $493 $(606) Cash capital expenditure $(610) $(156) Free cash flow $(117) $(762) Cash Flow • Cash generation of $493 million in operating cash flow and $(117) million of free cash flow − Operating cash flow negatively impacted by increased invento

  16. Slide 16: Maintaining full-year EPS guidance at $4.45-$4.65

    Maintaining full-year EPS guidance at $4.45-$4.65 October 2022 January 2023 Adj. EPS growth FY guidance FY guidance Adjusted EPS $4.45-$4.65 $4.45-$4.65 % growth YOY CFx (6)-(10)% (6)-(10)% COVID-19 headwind (17)-(15)% (18)-(16)% Adverse currency impact ~(2)% ~(1)% Core business growth + 8-10% + 8-1

  17. Slide 17: FY23 segment assumptions

    FY23 segment assumptions FY23 (Oct-22) FY23 (Jan-23) Comments • Sales raised to reflect Summit Health, Sales $130.5 - $134.0B $133.5 - $137.5B currency & 1Q sales above expectations WBA • AOI flat as Summit Health transaction AOI $4.7 - $4.9B $4.7 - $4.9B offsets partial sale of ABC • 1Q sales above

  18. Slide 18: FY23 corporate assumptions

    FY23 corporate assumptions $ millions FY23 (Oct-22) FY23 (Jan-23) Comments Adj. Tax Rate ~16% ~16% • 1Q tax rate timing related; full-year rate unchanged • Reflects higher interest from Summit Health Interest Expense $(500) - $(490) $(580) - $(560) transaction Share Repurchases $- $- • Anti-dilutive

  19. Slide 19: Solid start to fiscal 2023 with accelerated transformation to healthcare

    Solid start to fiscal 2023 with accelerated transformation to healthcare • Solid first quarter performance, broadly in line with expectations • Resilient core business with U.S. retail and Boots UK retail growth on top of strong prior year performances; U.S. script volume growth on track • VillageMD

  20. Slide 20: Q&A

    Q&A © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 20

  21. Slide 21: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  22. Slide 22: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  23. Slide 23: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET (LOSS) EARNINGS Three months ended November 30, Change vs. 1Q22 2022 2021 Amount Percent Net (loss) earnings attributable to Walgreens Boots Alliance,

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET (LOSS) EARNINGS Three months ended November 30, Change vs. 1Q22 2022 2021 Amount Percent Adjustments to net loss attributable to non-controlling intere

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2022 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,204

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2021 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 28,032

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income for U.S. Retail Pharmacy includes equity earnings in AmerisourceBergen. As a result of the two-month reporting lag, operating income for the three mon

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR U.S. HEALTHCARE SEGMENT Three months ended November 30, 2022 2021 Operating loss (GAAP) 1 $ (436) $ (45) 2 Acquisitio

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended November 30, 2022 2021 Equity earnings in AmerisourceBergen (GAAP) $ 53 $ 100 Acquisition-related i

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended November 30, 2022 Three months ended November 30, 2021 Loss before Earnings before income tax Income tax inc

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended November 30, 2022 2021 Net cash provided by operating activities (GAAP) $ 493 $ 1,099 Less: Additions to property, plant

Walgreens Boots Alliance — Q1 2023 Earnings Presentation on 6ix